Abstract
Objective To compare intra-arterial chemotherapy combined with intravesical chemotherapy with intravesical chemotherapy alone in the treatment of high-risk non-muscle invasive bladder cancer (HRBC) after thulium laser resection of a bladder tumor (TmLRBT).
Materials and methods
From January 2009 to December 2013, 283 patients with HRBC were randomly assigned to the combined group (group A, n = 141) or intravesical chemotherapy–alone group (group B, n = 142) after TmLRBT. Intra-arterial chemotherapy was administered after initial TmLRBT, with 3 courses at 4-week intervals. Each course consisted of cisplatin (50 mg/m2) and epirubicin (30 mg/m2). Intravesical chemotherapy was administered in both groups, including an immediate 50 mg of epirubicin instillation after TmLRBT and weekly maintenance for 8 weeks, followed by monthly maintenance for 1 year.
Results
The recurrence rate was 29.1% (41/141) in group A and 42.9% (61/142) in group B, with a significant difference (p = 0.01). The progression rate was 15.6% (22/141) in group A and 25.3% (36/142) in group B, with a significant difference (p = 0.039). Patients with concomitant carcinoma in situ (CIS) also had a lower recurrence rate and progression rate in group A compared to those in group B (p = 0.006 and p = 0.03, respectively). On univariate and multivariate logistic regression analyses, patients with low-grade histology had a higher reccurrence-free rate. Multivariate COX analysis of tumor-related factors suggested that concomitant CIS was the only significant prognostic factor associated with poorer recurrence-free survival and progression-free survival.
Conclusions
Intra-arterial chemotherapy combined with intravesical chemotherapy could reduce the risk of recurrence and progression compared to intravesical chemotherapy alone in HRBC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette–Guerin, and bacillus Calmette–Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766–773. doi:10.1016/j.eururo.2009.12.024
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639–653. doi:10.1016/j.eururo.2013.06.003
Hashine K, Kusuhara Y, Miura N, Shirato A, Sumiyoshi Y, Kataoka M (2009) Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer. Jpn J Clin Oncol 39(6):381–386. doi:10.1093/jjco/hyp023
Han B, Liang S, Jing Y, Cui D, An X, Zou Q, Wei H, Xia S (2014) Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection. Med Oncol 31(4):912. doi:10.1007/s12032-014-0912-9
Mokarim A, Uetani M, Hayashi N, Sakamoto I, Minami K, Ogawa Y, Ochi M, Matsuoka Y, Hayashi K, Nomata K (1997) Combined intraarterial chemotherapy and radiotherapy in the treatment of bladder carcinoma. Cancer 80(9):1776–1785
Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F (2004) Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer 101(11):2540–2548. doi:10.1002/cncr.20654
Azuma H, Inamoto T, Ibuki N, Ubai T, Kotake Y, Takahara K, Kiyama S, Nomi H, Uehara H, Komura K, Yamamoto K, Narumi Y, Katsuoka Y (2010) Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Int J Oncol 37(4):773–785
Chen J, Yao Z, Qiu S, Chen L, Wang Y, Yang J, Li J (2013) Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery. Cardiovasc Intervent Radiol 36(6):1521–1526. doi:10.1007/s00270-013-0594-2
Zhang Y, Xie L, Chen T, Xie W, Wu Z, Xu H, Xing C, Sha N, Shen Z, Qie Y, Liu X, Hu H, Wu C (2016) Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study. Onco Targets Ther 9:605–611. doi:10.2147/OTT.S99866
Zhong C, Guo S, Tang Y, Xia S (2010) Clinical observation on 2 micron laser for non-muscle-invasive bladder tumor treatment: single-center experience. World J Urol 28(2):157–161. doi:10.1007/s00345-010-0532-8
Kubota Y, Kakizaki H, Numasawa K, Suzuki K, Kato H (1989) Preoperative intra-arterial infusion chemotherapy for patients with bladder cancer. Eur Urol 16(3):189–194
Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guerin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247–256. doi:10.1016/j.eururo.2009.04.038
Solsona E, Iborra I, Ricos JV, Monros JL, Casanova JL, Almenar S (1995) The prostate involvement as prognostic factor in patients with superficial bladder tumors. J Urol 154(5):1710–1713
Solsona E, Iborra I, Ricos JV, Monros JL, Dumont R, Almenar S (1996) Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol 155(3):895–899 (discussion 899–900)
Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66(6 Suppl 1):90–107. doi:10.1016/j.urology.2005.06.135
Eapen L, Stewart D, Collins J, Peterson R (2004) Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 172(4 Pt 1):1276–1280
Chen MK, Qin ZK, Zhou FJ, Han H, Liu ZW, Li YH, Yao K, Hou GL, Ye YL, Zhang ZL, Tu H, Zhang XQ, Lu KS, Yang ZW (2009) Intra-arterial chemotherapy is reliable in preventing high-risk superficial bladder cancer from recurrence and progression. J Chemother 21(6):681–686. doi:10.1179/joc.2009.21.6.681
Azuma (2010) Novel bladder preservation therapy for locally invasive bladder cancer: Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Int J Oncol 37(4). doi:10.3892/ijo_00000727
Hashine K, Kusuhara Y, Miura N, Shirato A, Sumiyoshi Y, Kataoka M (2009) Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer. Jpn J Clin Oncol 39(6):381–386. doi:10.1093/jjco/hyp023
Acknowledgements
Funding was provided by Shanghai Science and Technology Committee (13DZ1940602), Shanghai Hospital Development Center (SHDC12014215) and Shanghai Municipal Commission of Health and Family Planning (20134423).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
F. Sun and R. Zhao contributed equally to this article.
Rights and permissions
About this article
Cite this article
Sun, F., Zhao, R., Zhu, Y. et al. A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer. Cancer Chemother Pharmacol 79, 1099–1107 (2017). https://doi.org/10.1007/s00280-017-3305-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-017-3305-x